| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/02/2000 | EP0975330A1 Pain reducing parenteral liposome formulation |
| 02/02/2000 | EP0975227A1 Topical use of probiotic bacillus spores to prevent or control microbial infections |
| 02/02/2000 | EP0975225A1 Fibrocyte-based cellular therapy formulations |
| 02/02/2000 | EP0975216A1 A method for treating papillomavirus infections |
| 02/02/2000 | EP0674516B1 Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds |
| 02/02/2000 | EP0616535B1 Method of treating viral infections |
| 02/02/2000 | CN1243445A Photochemotherapeutic compositions |
| 02/02/2000 | CN1243128A Semisynthesizing method for 20(S)-ginsenoside Rg3, and use in medicine |
| 02/01/2000 | US6020488 Small molecule inhibition of RNA/ligand binding |
| 02/01/2000 | US6020468 Antibodies directed against binding-associated epitopes |
| 02/01/2000 | US6020381 Use of 2-methylamino-2-phenylcyclohexanone for the treatment of protozoan infections |
| 02/01/2000 | US6020368 Microbiocides |
| 02/01/2000 | US6020358 Substituted phenethylsulfones and method of reducing TNFα levels |
| 02/01/2000 | US6020351 Carotenoid-nicotinamide-zinc compositions and methods of treatment using same |
| 02/01/2000 | US6020326 Method for inhibition of bone growth by anionic polymers |
| 02/01/2000 | US6020325 Method for inhibiting replication of HIV |
| 02/01/2000 | US6020309 Pharmaceuticals based on papillomaviruses |
| 02/01/2000 | US6020189 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 02/01/2000 | US6020182 Subunit respiratory syncytial virus vaccine preparation |
| 02/01/2000 | US6020167 Composition used as a therapeutic agent against chronic viral hepatic diseases |
| 02/01/2000 | US6020159 3-dehydroquinate synthase |
| 02/01/2000 | US6020157 Polynucleotides encoding HFGAN72X receptor |
| 02/01/2000 | US6020149 Combining a microbially required nucleotide phosphatase, a nucleoside phosphate and the substance to be tested, and assessing the extent of degradation of the nucleoside phosphate in the presence and absence of the substance |
| 02/01/2000 | US6020122 Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system |
| 02/01/2000 | US6019984 Bacterial preparations, method for producing same, and their use as vaccines |
| 02/01/2000 | US6019982 Mutant enterotoxin effective as a non-toxic oral adjuvant |
| 02/01/2000 | US6019981 Modified live Edwardsiella ictaluri against enteric septicemia in channel catfish |
| 02/01/2000 | US6019980 Nucleic acid respiratory syncytial virus vaccines |
| 02/01/2000 | US6019979 Anti-viral treatment with pertussis toxin B oligomer |
| 02/01/2000 | US6019978 Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| 02/01/2000 | US6019973 Vaccine against enterotoxin-induced illness. |
| 02/01/2000 | CA2173387C A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation |
| 02/01/2000 | CA2163348C Calanolide and related antiviral compounds, compositions, and uses thereof |
| 02/01/2000 | CA2047681C Vaccines for nontypable haemophilus influenzae |
| 01/29/2000 | CA2279316A1 Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases |
| 01/27/2000 | WO2000004141A2 Use of nucleic acid molecules as antiviral agents |
| 01/27/2000 | WO2000004044A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 01/27/2000 | WO2000004033A1 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate |
| 01/27/2000 | WO2000004031A1 Phosphorous organic compounds and their use |
| 01/27/2000 | WO2000004030A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 01/27/2000 | WO2000004016A2 Polymorph of ritonavir |
| 01/27/2000 | WO2000003973A1 Diacylhydrazine derivatives as integrin inhibitors |
| 01/27/2000 | WO2000003745A2 Polysaccharide vaccine for staphylococcal infections |
| 01/27/2000 | WO2000003743A2 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | WO2000003731A2 Vaccine to prevent and treat chlamydial infections |
| 01/27/2000 | WO2000003730A1 Urease based vaccine against helicobacter infection |
| 01/27/2000 | WO2000003723A1 Polymeric compounds and methods of formulating same |
| 01/27/2000 | WO2000003722A1 Nocathiacin antibiotics |
| 01/27/2000 | WO2000003710A1 Oxazolidinones to treat eye infections |
| 01/27/2000 | WO2000003709A1 Novel dna-cleaving antitumor agents |
| 01/27/2000 | WO2000003697A1 Pellets having a core coated with an antifungal and a polymer |
| 01/27/2000 | WO2000003696A1 Enteric coated pharmaceutical tablet and method of manufacturing |
| 01/27/2000 | WO2000003695A1 Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose |
| 01/27/2000 | WO1999064604A3 Attenuated pestiviruses |
| 01/27/2000 | WO1999064416A3 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2000 | WO1999061064A8 Mammalian genes encoding 3'-5' exonuclease |
| 01/27/2000 | WO1999057278A3 IMMUNIZATION AGAINST AND TREATMENT FOR INFECTION BY $i(H.PYLORI) |
| 01/27/2000 | WO1999055388A9 Substituted porphyrins |
| 01/27/2000 | WO1999039735A9 Live vaccine for human immunodeficiency virus |
| 01/27/2000 | DE19932216A1 Micro and nano particles useful e.g. as carriers of medicines, and agrochemicals, absorbents for cosmetic purposes, and for separations and analysis. |
| 01/27/2000 | DE19833476A1 New genetically modified, adherently growing CD34-negative stem cells for transfer of gene therapy constructs for treatment of immunodeficiency and metabolic disorders |
| 01/27/2000 | CA2674800A1 Polymorph of a pharmaceutical |
| 01/27/2000 | CA2337517A1 Novel dna-cleaving antitumor agents |
| 01/27/2000 | CA2337398A1 Nocathiacin antibiotics |
| 01/27/2000 | CA2337305A1 Diacylhydrazine derivatives |
| 01/27/2000 | CA2337103A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 01/27/2000 | CA2336143A1 Aminoalkylphosphonic acid derivatives and their use in treating infections |
| 01/27/2000 | CA2335381A1 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | CA2334811A1 Oxazolidinones to treat eye infections |
| 01/27/2000 | CA2334161A1 Use of nucleic acid molecules as antiviral agents |
| 01/27/2000 | CA2333931A1 Polysaccharide vaccine for staphylococcal infections |
| 01/26/2000 | EP0974668A1 Use of adenoviral E4 reading frames to improve expression of a gene of interest |
| 01/26/2000 | EP0974660A1 Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| 01/26/2000 | EP0974659A2 Viral nucleotide sequences |
| 01/26/2000 | EP0974598A2 New erythromycin derivatives, process for making them and their use as medicines |
| 01/26/2000 | EP0974347A1 Antiviral agents |
| 01/26/2000 | EP0974058A2 20 human secreted proteins |
| 01/26/2000 | EP0973942A2 Screening method for proline-rich proteins |
| 01/26/2000 | EP0973925A2 Matrix derived anti-hiv peptides and transdominant proteins |
| 01/26/2000 | EP0973924A1 Recombinant chimeric viruses and uses thereof |
| 01/26/2000 | EP0973909A2 Process for extracting and purifying recombinant, non-lipidised osp-protein |
| 01/26/2000 | EP0973903A2 Protein for inhibiting apoptosis |
| 01/26/2000 | EP0973892A2 28 human secreted proteins |
| 01/26/2000 | EP0973891A1 Human chemokine receptor-like chemokine |
| 01/26/2000 | EP0973888A1 Dendritic cell-derived growth factor |
| 01/26/2000 | EP0973886A2 METHOD AND CONJUGATE FOR TREATING $i(H. PYLORI) INFECTION |
| 01/26/2000 | EP0973879A2 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
| 01/26/2000 | EP0973878A1 Controlled dissolution cross-linked protein crystals |
| 01/26/2000 | EP0973864A1 Novel microorganisms |
| 01/26/2000 | EP0973819A1 Non-antigenic branched polymer conjugates |
| 01/26/2000 | EP0973803A1 Peptides useful for reducing symptoms of toxic shock syndrome |
| 01/26/2000 | EP0973802A1 Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses |
| 01/26/2000 | EP0973780A1 Antibacterial substituted 7-acylamino -3-(methylhydrazono) methyl-cephalosporins and intermediates |
| 01/26/2000 | EP0973779A1 Crystalline amine salt of cefdinir |
| 01/26/2000 | EP0973775A1 Pyrolopyrrolone derivatives |
| 01/26/2000 | EP0973772A1 Compounds |
| 01/26/2000 | EP0973768A1 Azole compounds, their production and their use |
| 01/26/2000 | EP0973767A1 Indazoles of cyclic ureas useful as hiv protease inhibitors |
| 01/26/2000 | EP0973755A1 Asymmetric synthesis of benzoxazinones via new intermediates |
| 01/26/2000 | EP0973753A2 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |